{"nctId":"NCT00851903","briefTitle":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial","startDateStruct":{"date":"2009-06"},"conditions":["Diabetes Mellitus, Type 2"],"count":112,"armGroups":[{"label":"Combination insulin glargine and sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Glargine","Drug: Sitagliptin","Drug: Metformin"]}],"interventions":[{"name":"Insulin Glargine","otherNames":["Lantus®"]},{"name":"Sitagliptin","otherNames":["Januvia®"]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Patients who completed the core study LANTU\\_C\\_02761 (NCT00751114) i.e. went through the visit 14 investigation,\n* HbA1c \\>= 7 %,\n* Dose of metformin compliant with the inclusion criteria of the core study (i.e. at least 1 g/day), and maintained stable for the duration of the core study\n* Ability and willingness to perform plasma blood glucose monitoring using the sponsor-provided plasma glucose meter and to complete the patient dairy,\n* Signed informed consent obtained prior any study procedure,\n* Willingness and ability to comply with the study protocol.\n\nExclusion Criteria:\n\n* Treatment with oral antidiabetic drugs other than metformin and sitagliptin in the core study,\n* Treatment with insulin other than Insulin Glargine in the core study (except in case of an emergency, for a period of time less than 7 days),\n* Treatment with a non-permitted drug during the core study,\n* Pregnant or lactating women,\n* In-patient care,\n* Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry in the core study),\n* Impaired renal function: serum creatinine \\>= 1.5 mg/dL (\\>= 133µmol/L) or \\>= 1.4 mg/dL (\\>=124 µmol/L) in men and women, respectively,\n* History of sensitivity to the study drugs or to drugs with a similar chemical structure,\n* Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\> 3 x upper limit of normal range,\n* Alcohol or drug abuse within the last year,\n* Night shift worker,\n* Presence of any condition (medical, psychological, social or geographical), current or anticipated that the investigator feels would compromise the patient's safety or limit the patient successful participation in the study,\n* Treatment with weight loss medications (e.g. sibutramine, orlistat, rimonabant),\n* History of pancreatitis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"71 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null}]}]}]},{"type":"SECONDARY","title":"HbA1c: Change From Baseline to Study Endpoint","description":"Change = study endpoint - baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"1.05"}]}]}]},{"type":"SECONDARY","title":"Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint","description":"SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).\n\nChange = study endpoint - baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.43","spread":"39.61"}]}]}]},{"type":"SECONDARY","title":"7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint","description":"7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.\n\nChange = study endpoint - baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.2","spread":"38.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.1","spread":"48.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.6","spread":"48.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"43.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.1","spread":"43.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.9","spread":"46.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.2","spread":"51.7"}]}]}]},{"type":"SECONDARY","title":"Insulin Dose","description":"Daily dose at the face-to-face visits","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With at Least One Episode of Symptomatic Hypoglycemia","description":"Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \\<= 70mg/dL \\[3.9 mmol/L\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Study Endpoint","description":"Change = study endpoint - baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"2.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":112},"commonTop":[]}}}